The research, published in the journal Diabetes, Obesity and Metabolism, tracked patients at Mount Sinai Health System and Wake Forest/Atrium Health. Results indicate that the prognostic tool functions as a dynamic, longitudinal monitor rather than a static snapshot. By identifying high-risk individuals early, clinicians increased the use of guideline-directed therapies, such as SGLT2 inhibitors and GLP-1 receptor agonists, which saw usage jump to 70% among high-risk patients at Mount Sinai.

Data show that patients who received these targeted therapies were nearly twice as likely to achieve objective risk reduction. Those designated as high-risk at the start of the study were 10.4 times more likely to face kidney failure compared to low-risk peers, but the intervention group experienced a 43% improvement in the rate of eGFR decline. Furthermore, nearly 29% of retested patients successfully migrated into a lower risk category over the 24-month period, demonstrating that precision diagnostics can effectively alter the clinical trajectory of chronic kidney disease.